诊断之外:B 型利尿肽对阿肯色州高危心血管产科项目孕妇的预后作用

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American journal of preventive cardiology Pub Date : 2024-09-01 DOI:10.1016/j.ajpc.2024.100816
Landon Bruich BS
{"title":"诊断之外:B 型利尿肽对阿肯色州高危心血管产科项目孕妇的预后作用","authors":"Landon Bruich BS","doi":"10.1016/j.ajpc.2024.100816","DOIUrl":null,"url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD Risk Assessment</div></div><div><h3>Background</h3><div>B-natriuretic peptide (BNP) is used as a screening biomarker for patients in cardio-obstetric programs. In nonpregnant females, obesity falsely lowers BNP, but its accuracy in the obese pregnant population is less known. We studied the diagnostic and prognostic utility of BNP in a predominantly obese, high-risk obstetric population in Arkansas.</div></div><div><h3>Methods</h3><div>We established a retrospective registry of pregnant patients who had undergone a BNP and echocardiographic assessment (within 30 days of each other) at the University of Arkansas Medical Center between January 1, 1995, to October 30, 2022. We assessed the relationship between BNP levels and left ventricular ejection fraction (LVEF) using Pearson correlation coefficients. We used receiver operating curves to identify an optimal BNP cutoff for predicting a reduced LVEF (&lt;50%), and cox regression analysis to determine a prognostic cutoff value. A p-value of &lt;0.05 indicated statistical significance. Analyses are performed using MedCalc software (Ostend, Belgium).</div></div><div><h3>Results</h3><div>We studied a total of n=315 pregnant patients with a median ±SD age of 29.8 years old (25-34) and BMI of 34 kg/m2 (34-41). In patients with a BMI of ≥ 35, there was no correlation between BNP and LVEF [-0.05 (-0.21 to 0.09, P = 0.47)] (Figure 1b). Of all variables examined, only LVEF of &lt;50% was predictive of maternal mortality with a 95% confidence interval of 1.1 to 25.1 and a P value of 0.04. Significant cutoff values for BMI and BNP are listed in Figure 1c-d.</div></div><div><h3>Conclusions</h3><div>BNP based screening in high-risk obstetric patients requires consideration of BMI in interpretation of test, paralleling the effect obesity has on BNP in a non-pregnant population. In conclusion, we recommend considering an echocardiography in obese, pregnant patients with a clinical suspicion of new or worsening heart failure, regardless of BNP level.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100816"},"PeriodicalIF":4.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BEYOND DIAGNOSIS: PROGNOSTIC UTILITY OF B-NATRIURETIC PEPTIDE IN PREGNANT PATIENTS PRESENTING TO ARKANSAS’ HIGH-RISK CARDIO-OBSTETRICS PROGRAM\",\"authors\":\"Landon Bruich BS\",\"doi\":\"10.1016/j.ajpc.2024.100816\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD Risk Assessment</div></div><div><h3>Background</h3><div>B-natriuretic peptide (BNP) is used as a screening biomarker for patients in cardio-obstetric programs. In nonpregnant females, obesity falsely lowers BNP, but its accuracy in the obese pregnant population is less known. We studied the diagnostic and prognostic utility of BNP in a predominantly obese, high-risk obstetric population in Arkansas.</div></div><div><h3>Methods</h3><div>We established a retrospective registry of pregnant patients who had undergone a BNP and echocardiographic assessment (within 30 days of each other) at the University of Arkansas Medical Center between January 1, 1995, to October 30, 2022. We assessed the relationship between BNP levels and left ventricular ejection fraction (LVEF) using Pearson correlation coefficients. We used receiver operating curves to identify an optimal BNP cutoff for predicting a reduced LVEF (&lt;50%), and cox regression analysis to determine a prognostic cutoff value. A p-value of &lt;0.05 indicated statistical significance. Analyses are performed using MedCalc software (Ostend, Belgium).</div></div><div><h3>Results</h3><div>We studied a total of n=315 pregnant patients with a median ±SD age of 29.8 years old (25-34) and BMI of 34 kg/m2 (34-41). In patients with a BMI of ≥ 35, there was no correlation between BNP and LVEF [-0.05 (-0.21 to 0.09, P = 0.47)] (Figure 1b). Of all variables examined, only LVEF of &lt;50% was predictive of maternal mortality with a 95% confidence interval of 1.1 to 25.1 and a P value of 0.04. Significant cutoff values for BMI and BNP are listed in Figure 1c-d.</div></div><div><h3>Conclusions</h3><div>BNP based screening in high-risk obstetric patients requires consideration of BMI in interpretation of test, paralleling the effect obesity has on BNP in a non-pregnant population. In conclusion, we recommend considering an echocardiography in obese, pregnant patients with a clinical suspicion of new or worsening heart failure, regardless of BNP level.</div></div>\",\"PeriodicalId\":72173,\"journal\":{\"name\":\"American journal of preventive cardiology\",\"volume\":\"19 \",\"pages\":\"Article 100816\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of preventive cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666667724001843\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667724001843","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

治疗领域心血管疾病/心血管疾病风险评估背景B-前列腺素肽(BNP)被用作心脏产科患者的筛查生物标志物。在非妊娠女性中,肥胖会使 BNP 下降,但其在肥胖妊娠人群中的准确性却鲜为人知。我们对阿肯色大学医学中心 1995 年 1 月 1 日至 2022 年 10 月 30 日期间接受 BNP 和超声心动图评估(在 30 天内)的妊娠患者进行了回顾性登记。我们使用皮尔逊相关系数评估了 BNP 水平与左心室射血分数(LVEF)之间的关系。我们利用接收者操作曲线确定了预测 LVEF 降低(50%)的最佳 BNP 临界值,并利用 Cox 回归分析确定了预后临界值。P值为<0.05表示统计学意义。结果我们共研究了 n=315 名妊娠患者,中位数±SD 年龄为 29.8 岁(25-34 岁),BMI 为 34 kg/m2(34-41 kg/m2)。在 BMI ≥ 35 的患者中,BNP 与 LVEF 之间没有相关性[-0.05(-0.21 至 0.09,P = 0.47)](图 1b)。在所有检查变量中,只有 LVEF 为 50%时可预测孕产妇死亡率,95% 置信区间为 1.1 至 25.1,P 值为 0.04。图 1c-d 列出了 BMI 和 BNP 的重要临界值。结论基于 BNP 的高危产科患者筛查需要在解释测试时考虑 BMI,这与肥胖对非妊娠人群 BNP 的影响类似。总之,我们建议临床怀疑新发或加重心衰的肥胖妊娠患者无论 BNP 水平如何,都应考虑进行超声心动图检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
BEYOND DIAGNOSIS: PROGNOSTIC UTILITY OF B-NATRIURETIC PEPTIDE IN PREGNANT PATIENTS PRESENTING TO ARKANSAS’ HIGH-RISK CARDIO-OBSTETRICS PROGRAM

Therapeutic Area

ASCVD/CVD Risk Assessment

Background

B-natriuretic peptide (BNP) is used as a screening biomarker for patients in cardio-obstetric programs. In nonpregnant females, obesity falsely lowers BNP, but its accuracy in the obese pregnant population is less known. We studied the diagnostic and prognostic utility of BNP in a predominantly obese, high-risk obstetric population in Arkansas.

Methods

We established a retrospective registry of pregnant patients who had undergone a BNP and echocardiographic assessment (within 30 days of each other) at the University of Arkansas Medical Center between January 1, 1995, to October 30, 2022. We assessed the relationship between BNP levels and left ventricular ejection fraction (LVEF) using Pearson correlation coefficients. We used receiver operating curves to identify an optimal BNP cutoff for predicting a reduced LVEF (<50%), and cox regression analysis to determine a prognostic cutoff value. A p-value of <0.05 indicated statistical significance. Analyses are performed using MedCalc software (Ostend, Belgium).

Results

We studied a total of n=315 pregnant patients with a median ±SD age of 29.8 years old (25-34) and BMI of 34 kg/m2 (34-41). In patients with a BMI of ≥ 35, there was no correlation between BNP and LVEF [-0.05 (-0.21 to 0.09, P = 0.47)] (Figure 1b). Of all variables examined, only LVEF of <50% was predictive of maternal mortality with a 95% confidence interval of 1.1 to 25.1 and a P value of 0.04. Significant cutoff values for BMI and BNP are listed in Figure 1c-d.

Conclusions

BNP based screening in high-risk obstetric patients requires consideration of BMI in interpretation of test, paralleling the effect obesity has on BNP in a non-pregnant population. In conclusion, we recommend considering an echocardiography in obese, pregnant patients with a clinical suspicion of new or worsening heart failure, regardless of BNP level.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
期刊最新文献
Editors’ message – December 2024 A vision for the future: ASPC's new educational offerings for 2025 Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES Effectiveness of behavior change techniques in eHealth-based cardiac rehabilitation in patients with coronary artery disease: A systematic review Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1